주식/증권 📉 부정적 Regenxbio outlines potential accelerated approval path for RGX-202 in 2027 following pivotal Phase III primary endpoint result Seeking Alpha - Market News 05/15/2026 12:32:27 AM 39회 원문 기사 보기